Group 1 - The company expects a significant reduction in loss for the first half of 2025, with an estimated loss not exceeding 33 million HKD, compared to a loss of 79.917 million HKD in the same period of 2024, representing a decrease of approximately 59% [1] - The improvement in operational performance is primarily attributed to successful cost control measures, which have led to an increase in gross margin and a reduction in administrative expenses [1] - The company also received compensation income of approximately 14 million HKD from insurance claims related to damages caused by heavy rainfall to construction sites in Hainan during 2024 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 （於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 盈利預告－虧損減少 本公告乃由中國生物科技服務控股有限公司（「本公司」，連同其附屬公司統稱為「本 集團」）根據香港聯合交易所有限公司GEM證券上市規則（「GEM上市規則」）第 17.10(2)(a)條及香港法例第571章《證券及期貨條例》第XIVA部項下之內幕消息條 文（定義見上市規則）而作出。 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者， 根據管理層目前可獲得之資料及對本集團截至2025年6月30日止6個月（「2025年中 期期間」）之最新未經審核綜合管理賬目（「管理賬目」）作出的初步審閱及評估，預 計2025年中期期間本公司擁有人應佔虧損將不多於33,000,000港元，較2024 ...

致：香港交易及結算所有限公司 公司名稱: 中國生物科技服務控股有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08037 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.1 HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.1 HKD | | 200,000,000 | 本月底法定/註冊股本總額： HKD 200,000,000 第 1 頁 共 10 頁 v 1.1.1 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的 ...

Company Overview - China Biotech Services Holdings Limited (stock code 08037.HK) is listed on the Hong Kong Stock Exchange and is headquartered in Hong Kong [2] - The company aims to create an integrated advanced biotechnology platform for cancer diagnosis and treatment, with business segments including PHC Standard Pathology Laboratory, AMDL Asia Molecular Diagnostics Laboratory, and Vcare Health Management [2] Financial Performance - As of December 31, 2024, the company reported total revenue of 65.2942 million yuan, a year-on-year decrease of 66.74% [1] - The net profit attributable to the parent company was -183 million yuan, a year-on-year decrease of 107.6% [1] - The gross profit margin was -7.01%, and the debt-to-asset ratio was 54.26% [1] Stock Performance - As of July 11, the stock price closed at 0.72 HKD per share, an increase of 10.77% with a trading volume of 765,000 shares and a turnover of 546,600 HKD [1] - Over the past month, the stock has seen a cumulative decline of 14.47%, while it has increased by 27.45% year-to-date, outperforming the Hang Seng Index by 19.78% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry (TTM) is -2.68 times, with a median of 1.17 times [1] - China Biotech Services has a P/E ratio of -3.2 times, ranking 93rd in the industry [1] - Other companies in the industry include Giant Medical Holdings (02393.HK) at 0.28 times, Jingjiu Health (00648.HK) at 0.38 times, Yihui Group (08161.HK) at 1.96 times, Global Medical (02666.HK) at 5.24 times, and Ruici Medical (01526.HK) at 5.4 times [1]

Core Viewpoint - China Biotechnology Services (08037) has entered into a non-binding memorandum of understanding with AXA Group and other partners to jointly develop affordable medical insurance products covering Boron Neutron Capture Therapy (BNCT) treatment costs and related services [1][2][3] Group 1: Collaboration Areas - Patient Medical Services: The company will provide treatment services including surgery, hospitalization, and post-operative rehabilitation for patients covered by insurance who are diagnosed for BNCT treatment at Hainan Pengbo BNCT Treatment Center and potentially other medical networks in the future [1] - Insurance Product Development and Marketing: Based on medical data provided by the company, partners will assist in developing competitive BNCT insurance products and promote them extensively in mainland China, Hong Kong, and potentially overseas markets [1][2] - Reinsurance Solutions: Partners will provide reinsurance solutions for BNCT insurance, leveraging their expertise in risk assessment and management to support pricing and risk control [2] Group 2: Market Expansion - Overseas Market Development: AXA and Gallagher will utilize their global insurance and reinsurance networks to help the company develop BNCT medical insurance products tailored for different countries and collaborate with local insurance companies [2] - Launch of BNCT Insurance in Hong Kong: AXA Hong Kong will be the first insurer to launch BNCT insurance products in the Hong Kong market [2] Group 3: Partner Profiles - AXA Group is a leading global insurance company operating in 50 markets, serving 95 million customers worldwide [3] - Qianhai Reinsurance, established in Shenzhen, is the first state-owned mixed-ownership reinsurance company in China, providing various reinsurance products and services [3] - Gallagher, a leading global insurance brokerage and risk management firm, offers professional insurance solutions and consulting services to clients worldwide [3] Group 4: Strategic Goals - The collaboration aims to develop affordable medical insurance products covering BNCT treatment costs to reduce the financial burden on patients and enhance treatment accessibility [3] - The partnership is expected to create synergies for the company's BNCT business, providing treatment to more patients in China and abroad, highlighting the company's commitment to improving global patient treatment outcomes [3]

Core Viewpoint - China Biotechnology Services (08037) announced that its indirect non-wholly owned subsidiary, Shanghai Longyao Biotechnology Co., Ltd., will present the Phase I clinical trial results of LY007 cell injection at two major international conferences in 2025, highlighting its potential to fill the treatment gap in CD20 CAR-T therapy [1] Group 1: Efficacy and Safety - LY007 features a unique OX40 co-stimulation signal design that significantly enhances T cell expansion and anti-tumor activity. Phase I clinical trial data shows that 92% of 12 patients with relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma experienced tumor reduction or disappearance, with a best complete response rate (BCRR) of 75%. One patient who failed CD19 CAR-T treatment achieved complete remission without severe cytokine release syndrome or neurotoxicity [2] Group 2: Differentiated Indication Strategy - LY007 offers a new treatment option for patients who failed CD19 CAR-T therapy or are CD19-negative relapsed. The CAR-T cells peaked at 46% to 80% of CD3+ T cells in patients. Shanghai Longyao plans to further promote international multicenter clinical research for LY007 at the International Conference on Malignant Lymphoma and the European Hematology Association meeting, exploring collaborations with European and American institutions. The company has laid out 14 global patents to support product commercialization and expansion into solid tumor indications. Over the past year, the Phase I clinical research results of LY007 have been presented at major global oncology and hematology conferences, indicating recognition and attention in the global academic field [3]

智通财经APP讯，中国生物科技服务(08037)发布公告，关于上海银行浦东分行(贷款人)向本公司的间接 非全资附属公司上海隆耀生物科技有限公司(上海隆耀)提供为期一年的银行授信。贷款人同意续订银行 授信，上海隆耀与贷款人订立小企业流动资金借款合同(借款合同)。根据借款合同，贷款人同意向上海 隆耀提供本金最多为人民币400万元的信贷额度，自借款合同日期起为期一年，以供用作一般流动资金 用途。 作为根据借款合同提供信贷额度的代价，本公司及本公司的主席、执行董事兼控股股东刘小林先生(刘 先生)各自订立以贷款人为受益人的普惠及小企业借款保证合同(统称"保证合同")，以无条件及不可撤回 的保证妥为及准时履行借款合同的义务，包括上海隆耀据此支付所有到期及应付款项。实际义务由保证 合同的条款管限。 本公司及刘先生以上海市中小微企业政策性融资担保基金管理中心(借款合同的另一名保证人)(该中心) 为受益人，分别签立《不可撤销信用反担保函》及《个人无限连带责任保证函》(统称"反担保函")，为 该中心提供反担保。根据反担保函，本公司及刘先生为该中心提供无限连带责任反担保。反担保的具体 范围、条款及年期由反担保函管限。 借款合同、保 ...

Precision Medicine and Cancer Treatment - The company achieved significant breakthroughs in precision medicine, focusing on CAR-T and BNCT therapies, solidifying its leadership in the cancer treatment sector[11] - A strategic investment of RMB 48 million was completed in February 2024 for the development of the LY007 CAR-T product, which has successfully completed 12 clinical trials[12] - The group aims to accelerate the commercialization of the CAR-T product LY007 and enter domestic Phase II clinical trials, seeking breakthroughs through patent exports[21] - Shanghai Longyao received approval for the IND application of LY007, the first CAR-T therapy targeting CD20 in China, with 12 patients successfully treated as of the report date[30] - The company is actively pursuing strategic collaborations and international technology licensing to drive growth in its three core precision medicine business segments[11] - The company plans to enhance its cancer precision testing and treatment integrated biotech service platform, focusing on innovative drug development and clinical transformation[11] Boron Neutron Capture Therapy (BNCT) Development - The company secured a bank loan of RMB 50 million for the construction of the Boron Neutron Capture Therapy Hospital, which is expected to begin operations in Q4 2025[13] - The company faced delays in the Boron Neutron Capture Therapy Hospital's construction due to extreme weather conditions, necessitating emergency repair plans[13] - The construction of the boron neutron capture therapy center is ongoing, with the opening expected to be delayed to Q4 2025 due to severe weather impacts[34] - The group plans to ensure the opening of BNCT hospitals and develop a network of BNCT treatment centers in Asia, aiming for the first sales of BNCT equipment[21] - The company has entered into agreements to purchase boron neutron capture therapy equipment and drugs, aiming to be the first provider of this advanced cancer treatment service in the Greater China region[79] Financial Performance and Revenue - The group recorded a revenue of approximately HKD 70,509,000 for the fiscal year ending December 31, 2024, representing a significant decrease of about 66.74% compared to HKD 211,985,000 for the fiscal year ending December 31, 2023[24] - The revenue from medical laboratory testing and health check services decreased by 79.70% from approximately HKD 192,910,000 in 2023 to about HKD 39,158,000 in 2024[26] - The sales revenue of the healthcare and pharmaceutical products segment decreased from approximately HKD 881,000 in 2023 to about HKD 686,000 in 2024, a decline of approximately 22.13%[31] - The insurance brokerage services segment saw a significant revenue increase from approximately HKD 18,163,000 in 2023 to about HKD 30,600,000 in 2024, an increase of 68.47%[35] - The logistics services segment's revenue increased from approximately HKD 31,000 in 2023 to about HKD 65,000 in 2024, representing a growth of 110%[36] - The company recorded a gross loss of approximately HKD 4,940,000 in 2024, a decrease of about HKD 39,264,000 compared to a gross profit of HKD 34,324,000 in 2023[38] - The company recorded a net loss attributable to shareholders of approximately HKD 198,146,000 for the fiscal year 2024, an increase from HKD 95,447,000 in fiscal year 2023[59] - The increase in net loss was primarily due to a decrease in demand for COVID-19 nucleic acid testing and intensified market competition in medical laboratory testing and health check services[59] Strategic Collaborations and Partnerships - The company signed a memorandum of cooperation with the Hong Kong-Shenzhen Innovation and Technology Park in April 2024, enhancing its integration into the Greater Bay Area biotech ecosystem[15] - The group has established a joint laboratory with Shanghai Guanhua Pharmaceutical Technology Co., Ltd. to enhance its one-stop testing solution capabilities, expanding its service footprint in the Asia-Pacific region[19] - The company has partnered with Abbott to upgrade its medical laboratory, becoming the first private lab in Hong Kong to install a customized virtual biochemical immunoassay system, improving efficiency and reducing human error[75] - The company has established partnerships with several domestic hospitals, including Huashan Hospital, to provide treatment services at the boron neutron capture therapy center set to open in Q4 2025[80] Corporate Governance and Management - The company has adopted the GEM Listing Rules Appendix C1 Corporate Governance Code principles and has complied with the code provisions, with one exception regarding attendance at the annual general meeting[123] - The board consists of three executive directors and three independent non-executive directors as of December 31, 2024[125] - The company emphasizes the importance of corporate governance for its success and has implemented measures to ensure transparency and accountability to shareholders[123] - The board is responsible for the overall strategic development of the group and monitoring management, administration, and operations[130] - The company has established appropriate insurance for directors to protect against legal claims[129] Employee and Operational Metrics - The group employed a total of 141 full-time employees as of December 31, 2024, down from 162 in 2023[106] - Total employee costs for the fiscal year 2024 were approximately HKD 65,779,000, a decrease from HKD 92,607,000 in the fiscal year 2023[106] - Contributions to the mandatory provident fund plan amounted to approximately HKD 2,231,000 for the fiscal year 2024, down from HKD 2,996,000 in the fiscal year 2023[107] Risk Management and Compliance - The company has adopted a risk management system aligned with the COSO framework to ensure operational effectiveness and compliance[176] - The group has not established an internal audit function due to cost considerations but will continue to review the necessity of such a department annually[178] - The company has implemented measures to ensure the accuracy and timeliness of its disclosures regarding inside information[178] Environmental, Social, and Governance (ESG) Initiatives - The company’s ESG report for 2024 covers key business segments including medical laboratory testing services in Hong Kong and tumor immunotherapy in China[197] - The board oversees the implementation of ESG policies and strategies, emphasizing the importance of a robust ESG framework for sustainable development[200] - The report covers the promotion of ESG concepts to employees and clients since 2016, with a summary of results expected for the 2024 fiscal year[198]

Financial Performance - The company's revenue for the year ended December 31, 2024, was HKD 70,509,000, a decrease of 66.7% compared to HKD 211,985,000 in 2023[3] - The gross loss for the year was HKD 4,940,000, compared to a gross profit of HKD 34,324,000 in the previous year[3] - Operating loss increased to HKD 143,048,000 from HKD 127,674,000 year-over-year[3] - The total comprehensive loss for the year was HKD 268,982,000, compared to HKD 174,253,000 in 2023, representing a 54.3% increase[4] - Basic and diluted loss per share was HKD 0.205, compared to HKD 0.099 in the previous year[4] - The group reported a loss of approximately HKD 251,854,000 for the year ended December 31, 2024[14] - The company reported a total loss before tax of HKD 252,797,000 for the year ended December 31, 2024, compared to a loss of HKD 142,025,000 in 2023[27][29] - The group recorded a net loss attributable to shareholders of approximately HKD 198,146,000 in 2024, an increase from HKD 95,447,000 in 2023[69] Assets and Liabilities - Total assets decreased to HKD 529,955,000 from HKD 662,362,000, a decline of 20.0%[5] - Total equity decreased to HKD 242,388,000 from HKD 490,726,000, a drop of 50.6%[6] - The total liabilities of the company as of December 31, 2024, were HKD 287,567,000, compared to HKD 171,636,000 in 2023[27][29] - As of December 31, 2024, the group's current liabilities exceeded its current assets by approximately HKD 129,519,000[14] - The total current assets decreased from HKD 39,636,000 in 2023 to HKD 25,416,000 in 2024, a decline of about 36%[35] Revenue Breakdown - Revenue from medical laboratory testing and health check services was HKD 39,158,000, down from HKD 192,910,000, indicating a decrease of about 79.7%[23] - Insurance brokerage services revenue increased to HKD 30,600,000 from HKD 18,163,000, reflecting a growth of approximately 68.4%[23] - The segment loss for the medical and healthcare services division was HKD 100,150,000 for the year ended December 31, 2024[27] - The overall demand for medical laboratory testing and health check services was weaker than expected in fiscal year 2024, attributed to local consumption recovery challenges post-pandemic[52] Financing and Capital Structure - The company has issued convertible bonds amounting to HKD 41,635,000, which were not present in the previous year[6] - The company plans to redeem USD 4,000,000 (approximately HKD 31,400,000) of the convertible bonds on December 17, 2024[40] - A new convertible bond issuance of USD 6,000,000 (approximately HKD 47,100,000) occurred on December 27, 2024, with an initial conversion price of HKD 1.20 per share[41] - The company has secured loans from controlling shareholders amounting to approximately HKD 24,772,000 as of December 31, 2024, with a fixed interest rate of 10%[90] - The group is actively seeking alternative financing and loans to meet its current financial obligations and future operational and capital expenditures, having secured approximately HKD 6,000,000 in additional loans as of the financial statement approval date[16] Impairment and Losses - The company reported a net impairment loss on property, plant, and equipment of HKD 52,713,000, compared to HKD 16,186,000 in 2023[3] - The impairment loss recognized for construction projects due to damage was approximately HKD 52,713,000[24] - The group recognized impairment losses of approximately HKD 13,374,000 and HKD 2,584,000 for intangible assets and right-of-use assets, respectively, related to the acquisition of DVF[67] Strategic Initiatives and Future Plans - The group has entered into a strategic cooperation framework agreement with Shenzhen Huada Gene Technology Co., Ltd., and an investment intention letter with investors for a potential investment of RMB 20 million to 30 million in Pengbo (Hainan)[16] - The company aims to be the first provider of boron neutron capture therapy services in Greater China, targeting inoperable, locally advanced, or locally recurrent head and neck cancer patients[85] - The company has launched a series of early health screening tests, including diabetes and HPV, to capitalize on the increased public awareness of health due to the pandemic[82] - The company continues to develop its anti-tumor cell therapy products, with clinical trials for its CAR-T drug progressing as planned[83] Governance and Compliance - The board of directors includes three executive directors and three independent non-executive directors[129] - The company has maintained compliance with the GEM listing rules regarding public float requirements[128] - The independent auditor's report indicated a significant uncertainty regarding the group's ability to continue as a going concern[112]

Financial Performance - Revenue for the six months ended June 30, 2024, was HKD 32,449,000, a decrease of 82.2% compared to HKD 182,357,000 in the same period of 2023[2]. - Gross loss for the period was HKD 3,107,000, compared to a gross profit of HKD 61,326,000 in the previous year[2]. - Operating loss increased to HKD 124,588,000 from HKD 34,067,000 year-on-year, reflecting a significant decline in performance[2]. - Total comprehensive loss for the period was HKD 132,973,000, compared to HKD 44,983,000 in the same period last year[4]. - The company reported a basic and diluted loss per share of HKD 0.083, compared to HKD 0.032 in the previous year[4]. - The group recorded a pre-tax loss of HKD 126,258 thousand for the period, compared to a pre-tax loss of HKD 24,677 thousand in the same period last year[15]. - The total loss for the period was HKD 125,731 thousand, compared to a loss of HKD 27,721 thousand in the previous year, indicating a significant increase in losses[16]. - For the six months ended June 30, 2024, the company reported a loss attributable to owners of approximately HKD 79,917,000, compared to a loss of HKD 30,484,000 for the same period in 2023[36]. Assets and Liabilities - Total assets as of June 30, 2024, were HKD 630,553,000, down from HKD 662,362,000 at the end of 2023[6]. - Non-current assets increased to HKD 238,275,000 from HKD 100,535,000, indicating substantial investment in property, plant, and equipment[5]. - Current assets decreased to HKD 473,486,000 from HKD 401,196,000, with a notable reduction in cash and bank balances[5]. - Equity attributable to owners of the company decreased to HKD 390,217,000 from HKD 462,754,000, reflecting a decline in shareholder value[6]. - Total liabilities increased to HKD 249,229,000 as of June 30, 2024, compared to HKD 171,636,000 as of December 31, 2023[18]. Cash Flow - For the six months ended June 30, 2024, the net cash used in operating activities was HKD (95,539) thousand, compared to HKD 310,855 thousand for the same period in 2023, indicating a significant decrease in cash flow from operations[10]. - The total cash and cash equivalents at the end of the period decreased to HKD 33,241 thousand from HKD 245,396 thousand a year earlier, indicating a decline in liquidity[10]. - The company reported a net decrease in cash and cash equivalents of HKD (38,449) thousand for the period, compared to an increase of HKD 155,283 thousand in the same period last year, highlighting a shift in cash management[10]. Revenue Breakdown - Revenue from medical laboratory testing and health check services was HKD 19,729 thousand, down from HKD 170,525 thousand year-on-year, indicating a decrease of about 88.4%[15]. - The insurance brokerage services generated revenue of HKD 12,255 thousand, compared to HKD 11,467 thousand in the previous year, reflecting an increase of approximately 6.9%[13]. - The logistics services segment reported revenue of HKD 28 thousand, significantly up from HKD 9 thousand in the prior year, marking a growth of approximately 211.1%[13]. - The decline in revenue was primarily due to the cessation of mandatory COVID-19 nucleic acid testing services by the Hong Kong government, which significantly impacted income[61]. Strategic Focus - The company is focusing on precision treatment and diagnosis as part of its future biotech platform strategy[1]. - The company continues to focus on providing medical laboratory testing services and health check services in Hong Kong, as well as cancer immunotherapy and health management services in China[12]. - The company is engaged in the sale and distribution of health-related and pharmaceutical products in both China and Hong Kong, indicating ongoing market expansion efforts[12]. Investments and Capital Expenditures - Capital expenditures for the six months ended June 30, 2024, were HKD 161,813,000, a significant increase from HKD 16,730,000 in the same period of 2023[19]. - The company completed a capital injection agreement amounting to RMB 49,960,000 into Shanghai Longyao, acquiring a 5.57% equity interest[46]. - The company has capital commitments of HKD 91,938,000 for boron neutron capture therapy equipment and center construction, down from HKD 208,295,000 as of December 31, 2023[54]. Shareholder Information - The company did not recommend any dividend for the six months ended June 30, 2024, consistent with the previous period[36]. - As of June 30, 2024, the total issued shares were 963,231,150, with Liu Xiaolin holding approximately 54.97% of the shares[86]. - Major shareholders include entities holding significant stakes, such as 529,500,546 shares (54.97%) and 187,903,805 shares (19.51%) respectively[90]. Corporate Governance - The board emphasizes the importance of corporate governance for the company's success and has implemented measures to ensure compliance with laws and regulations[107]. - The audit committee, consisting of three independent non-executive directors, oversees the financial reporting process and internal controls[108]. - The company has adopted a code of conduct for directors regarding securities trading, confirming compliance during the interim period of 2024[106].